Core Viewpoint - Hyperscale Data, Inc. has entered into a Securities Purchase Agreement for up to $100 million in financing from Ault & Company, Inc., which will involve the issuance of Series H Convertible Preferred Stock to support expansion and operational needs [1][3][4]. Financing Details - The financing will involve the issuance of up to $100 million in Series H Convertible Preferred Stock, which will be senior to all other classes of preferred stock except for Series C and Series G [1][2]. - Each Preferred Share has a stated value of $1,000 and can be converted into Common Stock at a conversion price that is the greater of $0.10 or a price based on the market conditions [2]. - The Preferred Shares will pay an annual dividend of 9.5%, which may be paid in shares of Class A Common Stock during the first two years [2]. Use of Proceeds - Proceeds from the financing will be allocated for the expansion of the MI data center, repayment of outstanding debts, and general working capital [3]. Market Perception - The willingness of Ault & Company to invest an additional $100 million indicates a belief that the market has undervalued Hyperscale Data, as the conversion price of the Preferred Shares is higher than the current market price [4]. Transaction Conditions - The Agreement allows for multiple closings through December 31, 2026, subject to customary closing conditions, regulatory, and stockholder approvals [5]. - The conversion of the Preferred Shares is subject to conditions that include receiving financing by Ault & Company [5]. Company Overview - Hyperscale Data operates a data center through its subsidiary Sentinum, focusing on digital asset mining and services for the AI ecosystem [9]. - The company is also involved in acquiring undervalued businesses and disruptive technologies through its subsidiary Ault Capital Group [9].

Core Viewpoint - Oragenics, Inc. has announced a public offering of up to 800,000 shares of Series H Convertible Preferred Stock and Warrants, aiming to raise approximately $20 million to fund ongoing clinical trials and other corporate purposes [1][2]. Group 1: Offering Details - The offering includes 800,000 shares of Preferred Stock and Warrants to purchase an additional 800,000 shares at an exercise price of $25.00 per share [1]. - The combined public offering price for each share of Preferred Stock and accompanying Warrant is set at $25.00 [1]. - The Preferred Stock can be converted into common stock at a conversion price of $2.50 per share [1]. Group 2: Financial Proceeds and Use - Gross proceeds from the offering are expected to be approximately $20 million before deducting fees and expenses [2]. - The net proceeds will be used to fund ongoing ONP-2 concussion clinical trials, repay a $3 million bridge note, and for general corporate purposes [2]. Group 3: Placement Agent and Regulatory Compliance - Dawson James Securities, Inc. is acting as the sole placement agent for the offering [3]. - The offering is being conducted under a registration statement filed with the SEC, which became effective on June 30, 2025 [4].